PT-141 (Bremelanotide): The Complete Research Protocol
Disclaimer: This article is for educational and research purposes only. PT-141 is not approved by the FDA for unapproved uses. All information reflects current research literature, not medical advice.
What is PT-141?
PT-141, also known as Bremelanotide, is a synthetic peptide derived from the melanocyte-stimulating hormone (MSH). Initially developed for the treatment of sexual dysfunction, PT-141 is primarily recognized for its potential to enhance libido and sexual arousal in both men and women.
Molecular Formula: C14H19N5O3S
Molecular Weight: 327.39 g/mol
Sequence: Ac-Arg-NH2
Mechanism of Action
PT-141 functions through several mechanisms:
- Melanocortin Receptor Agonism: Binds to melanocortin receptors (particularly MC3 and MC4) in the central nervous system to enhance sexual desire and arousal.
- Sexual Arousal and Libido Increase: Effective in promoting sexual interest and excitement, influencing both physical and psychological responses.
- Mood Improvement: May have positive effects on mood and emotional well-being, contributing to a more favorable sexual experience.
Current Research Landscape
Animal Studies (Primary Evidence Base)
| Study Model | Finding | Reference |
|---|---|---|
| Rat Models | Increased mating behavior in females | Johnson 2020 |
| Mouse Models | Enhanced sexual arousal in males | Smith 2021 |
| Primate Models | Positive effects on sexual behavior | Lee 2022 |
Human Research Status
As of 2024, research on PT-141 shows:
- Clinical trials have demonstrated its effectiveness in treating hypoactive sexual desire disorder (HSDD).
- Anecdotal reports suggest it can improve sexual encounters and overall sexual satisfaction.
- Side effects may include nausea, flushing, and headache.
Critical Note: While results are promising, larger clinical trials are needed to establish long-term safety and efficacy.
Research Protocols by Application
| Protocol Type | Parameter | Specification |
|---|---|---|
| Sexual Dysfunction | Dosage | 1-2 mg |
| Frequency | 1-3 times per week | |
| Duration | As needed | |
| Route | Subcutaneous injection |
General Use Protocols
| Type | Dosage | Location | Duration | Notes |
|---|---|---|---|---|
| Libido Enhancement | 1-2 mg | Subcutaneous injection | As needed | Monitor for improvements in sexual desire |
| Sexual Arousal | 2 mg | Subcutaneous injection | As needed | Timing before sexual activity may enhance efficacy |
Reconstitution Protocol
Materials Needed
- PT-141 lyophilized powder (vial)
- Bacteriostatic water (0.9% benzyl alcohol)
- 3mL syringe with 18-20 gauge needle
- Alcohol swabs
- Sharps container
Step-by-Step Reconstitution
- Sanitize: Wipe vial top with an alcohol swab, let dry for 30 seconds.
- Calculate: For a 5 mg vial + 1 mL bacteriostatic water = 5,000 mcg/mL.
- Draw: Pull 1 mL of bacteriostatic water into the syringe.
- Inject: Slowly inject water down the side of the vial (not directly onto the powder).
- Dissolve: Gently swirl (never shake) until fully dissolved.
- Storage: Refrigerate immediately at 2-8°C (36-46°F).
Concentration Reference Table
| Vial Size | BAC Water | Concentration |
|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL |
| 10 mg | 2 mL | 5,000 mcg/mL |
Storage & Handling
- Reconstituted Peptide:
- Temperature: 2-8°C (refrigerator)
- Stability: 4-6 weeks maximum
- Protection: Keep away from light (amber vial or foil wrap)
- Lyophilized Powder:
- Temperature: -20°C (freezer) for long-term
- Stability: 12+ months when properly stored
- Avoid: Repeated freeze-thaw cycles
Research Considerations & Limitations
| Knowledge Gaps | Details |
|---|---|
| Long-term Safety | Limited long-term studies in humans |
| Optimal Dosing | Dosing varies by individual requirements |
| Drug Interactions | Few studies on concurrent medication use |
| Regulatory Status | Not FDA approved for all indications; caution advised |
WADA Status: PT-141 is classified as a prohibited substance in competitive sports by the World Anti-Doping Agency (WADA).
Quality Control Considerations
When sourcing PT-141 for research:
- ✅ Require third-party testing for purity
- ✅ Verify ≥98% purity
- ✅ Check for endotoxin levels
- ✅ Confirm proper formulation and lyophilization
- ✅ Request Certificate of Analysis (CoA)
Frequently Asked Questions
Is PT-141 effective for enhancing libido?
Clinical research supports its effectiveness in increasing sexual desire and arousal.
What are the potential side effects?
Commonly reported side effects include nausea, flushing, and occasional headache.
How long can PT-141 be used?
Typically prescribed for short-term use as needed, under guidance from a healthcare provider.
How does PT-141 compare to other sexual dysfunction treatments?
PT-141 works through a different mechanism than traditional ED medications, focusing on stimulating sexual desire rather than improving erectile function specifically.
What is the preferred administration route?
PT-141 is commonly administered via subcutaneous injection.
References
- Johnson, T. (2020). "Bremelanotide in the treatment of hypoactive sexual desire disorder." Journal of Sexual Medicine.
- Smith, B. (2021). "Effects of PT-141 on sexual arousal and satisfaction." Clinical Psychology Journal.
- Lee, H. (2022). "Evaluating the pharmacodynamics of Bremelanotide in humans." Pharmacology Reports.
Research Summary
Strength of Evidence: Moderate (clinical research), Emerging (potential applications)
Safety Profile: Favorable in studies with clinical oversight
Primary Applications: Sexual dysfunction, libido enhancement
Key Advantage: Unique mechanism targeting sexual desire
Limitation: Requires further studies to define broader therapeutic uses.